• Something wrong with this record ?

Distinct cytokine profiles associated with COVID-19 severity and mortality

K. Dorgham, P. Quentric, M. Gökkaya, S. Marot, C. Parizot, D. Sauce, A. Guihot, CE. Luyt, M. Schmidt, J. Mayaux, A. Beurton, L. Le Guennec, S. Demeret, E. Ben Salah, A. Mathian, H. Yssel, B. Combadiere, C. Combadiere, C. Traidl-Hoffmann, S....

. 2021 ; 147 (6) : 2098-2107. [pub] 20210422

Language English Country United States

Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21018517

BACKGROUND: Markedly elevated levels of proinflammatory cytokines and defective type-I interferon responses were reported in patients with coronavirus disease 2019 (COVID-19). OBJECTIVE: We sought to determine whether particular cytokine profiles are associated with COVID-19 severity and mortality. METHODS: Cytokine concentrations and severe acute respiratory syndrome coronavirus 2 antigen were measured at hospital admission in serum of symptomatic patients with COVID-19 (N = 115), classified at hospitalization into 3 respiratory severity groups: no need for mechanical ventilatory support (No-MVS), intermediate severity requiring mechanical ventilatory support (MVS), and critical severity requiring extracorporeal membrane oxygenation (ECMO). Principal-component analysis was used to characterize cytokine profiles associated with severity and mortality. The results were thereafter confirmed in an independent validation cohort (N = 86). RESULTS: At time of hospitalization, ECMO patients presented a dominant proinflammatory response with elevated levels of TNF-α, IL-6, IL-8, and IL-10. In contrast, an elevated type-I interferon response involving IFN-α and IFN-β was characteristic of No-MVS patients, whereas MVS patients exhibited both profiles. Mortality at 1 month was associated with higher levels of proinflammatory cytokines in ECMO patients, higher levels of type-I interferons in No-MVS patients, and their combination in MVS patients, resulting in a combined mortality prediction accuracy of 88.5% (risk ratio, 24.3; P < .0001). Severe acute respiratory syndrome coronavirus 2 antigen levels correlated with type-I interferon levels and were associated with mortality, but not with proinflammatory response or severity. CONCLUSIONS: Distinct cytokine profiles are observed in association with COVID-19 severity and are differentially predictive of mortality according to oxygen support modalities. These results warrant personalized treatment of COVID-19 patients based on cytokine profiling.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018517
003      
CZ-PrNML
005      
20210830100118.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jaci.2021.03.047 $2 doi
035    __
$a (PubMed)33894209
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dorgham, Karim $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France
245    10
$a Distinct cytokine profiles associated with COVID-19 severity and mortality / $c K. Dorgham, P. Quentric, M. Gökkaya, S. Marot, C. Parizot, D. Sauce, A. Guihot, CE. Luyt, M. Schmidt, J. Mayaux, A. Beurton, L. Le Guennec, S. Demeret, E. Ben Salah, A. Mathian, H. Yssel, B. Combadiere, C. Combadiere, C. Traidl-Hoffmann, S. Burrel, AG. Marcelin, Z. Amoura, G. Voiriot, AU. Neumann, G. Gorochov
520    9_
$a BACKGROUND: Markedly elevated levels of proinflammatory cytokines and defective type-I interferon responses were reported in patients with coronavirus disease 2019 (COVID-19). OBJECTIVE: We sought to determine whether particular cytokine profiles are associated with COVID-19 severity and mortality. METHODS: Cytokine concentrations and severe acute respiratory syndrome coronavirus 2 antigen were measured at hospital admission in serum of symptomatic patients with COVID-19 (N = 115), classified at hospitalization into 3 respiratory severity groups: no need for mechanical ventilatory support (No-MVS), intermediate severity requiring mechanical ventilatory support (MVS), and critical severity requiring extracorporeal membrane oxygenation (ECMO). Principal-component analysis was used to characterize cytokine profiles associated with severity and mortality. The results were thereafter confirmed in an independent validation cohort (N = 86). RESULTS: At time of hospitalization, ECMO patients presented a dominant proinflammatory response with elevated levels of TNF-α, IL-6, IL-8, and IL-10. In contrast, an elevated type-I interferon response involving IFN-α and IFN-β was characteristic of No-MVS patients, whereas MVS patients exhibited both profiles. Mortality at 1 month was associated with higher levels of proinflammatory cytokines in ECMO patients, higher levels of type-I interferons in No-MVS patients, and their combination in MVS patients, resulting in a combined mortality prediction accuracy of 88.5% (risk ratio, 24.3; P < .0001). Severe acute respiratory syndrome coronavirus 2 antigen levels correlated with type-I interferon levels and were associated with mortality, but not with proinflammatory response or severity. CONCLUSIONS: Distinct cytokine profiles are observed in association with COVID-19 severity and are differentially predictive of mortality according to oxygen support modalities. These results warrant personalized treatment of COVID-19 patients based on cytokine profiling.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    12
$a COVID-19 $x imunologie $x mortalita $x terapie $7 D000086382
650    _2
$a cytokiny $x imunologie $7 D016207
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a umělé dýchání $7 D012121
650    _2
$a SARS-CoV-2 $x imunologie $7 D000086402
650    12
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Quentric, Paul $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France
700    1_
$a Gökkaya, Mehmet $u Department of Environmental Medicine, Faculty of Medicine, University Hospital of Augsburg, Augsburg, Germany; Institute of Environmental Medicine (IEM), Technical University of Munich and Helmholtz Zentrum München, Augsburg, Germany
700    1_
$a Marot, Stéphane $u Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département de Virologie, Paris, France
700    1_
$a Parizot, Christophe $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Département d'Immunologie, Paris, France
700    1_
$a Sauce, Delphine $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France
700    1_
$a Guihot, Amélie $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Département d'Immunologie, Paris, France
700    1_
$a Luyt, Charles-Edouard $u AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Institut de Cardiologie, Paris, France; Sorbonne Université, Inserm, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
700    1_
$a Schmidt, Matthieu $u AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Institut de Cardiologie, Paris, France; Sorbonne Université, Inserm, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
700    1_
$a Mayaux, Julien $u AP-HP, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive - Réanimation, Paris, France
700    1_
$a Beurton, Alexandra $u AP-HP, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive - Réanimation, Paris, France; Sorbonne Université, Inserm UMR S 1158, Neurophysiologie respiratoire expérimentale et clinique, Paris, France
700    1_
$a Le Guennec, Loic $u Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département de Neurologie, Unité de Médecine Intensive et Réanimation Neurologique, Paris, France
700    1_
$a Demeret, Sophie $u Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département de Neurologie, Unité de Médecine Intensive et Réanimation Neurologique, Paris, France
700    1_
$a Ben Salah, Elyes $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Département d'Immunologie, Paris, France
700    1_
$a Mathian, Alexis $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne 2, Institut E3M, Paris, France
700    1_
$a Yssel, Hans $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France
700    1_
$a Combadiere, Béhazine $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France
700    1_
$a Combadiere, Christophe $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France
700    1_
$a Traidl-Hoffmann, Claudia $u Department of Environmental Medicine, Faculty of Medicine, University Hospital of Augsburg, Augsburg, Germany; Institute of Environmental Medicine (IEM), Technical University of Munich and Helmholtz Zentrum München, Augsburg, Germany; Christine Kühne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland
700    1_
$a Burrel, Sonia $u Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département de Virologie, Paris, France
700    1_
$a Marcelin, Anne-Geneviève $u Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département de Virologie, Paris, France
700    1_
$a Amoura, Zahir $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne 2, Institut E3M, Paris, France
700    1_
$a Voiriot, Guillaume $u AP-HP, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris, France
700    1_
$a Neumann, Avidan U $u Department of Environmental Medicine, Faculty of Medicine, University Hospital of Augsburg, Augsburg, Germany; Institute of Environmental Medicine (IEM), Technical University of Munich and Helmholtz Zentrum München, Augsburg, Germany; Institute of Experimental Medicine (IEM), Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Gorochov, Guy $u Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Département d'Immunologie, Paris, France. Electronic address: guy.gorochov@sorbonne-universite.fr
773    0_
$w MED00002505 $t The Journal of allergy and clinical immunology $x 1097-6825 $g Roč. 147, č. 6 (2021), s. 2098-2107
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33894209 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100118 $b ABA008
999    __
$a ok $b bmc $g 1689574 $s 1138963
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 147 $c 6 $d 2098-2107 $e 20210422 $i 1097-6825 $m Journal of allergy and clinical immunology $n J Allergy Clin Immunol $x MED00002505
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options